We had previously reported that transduction of the channelrhodopsin-2 (ChR2) gene into retinal ganglion cells restores visual function in genetically blind, dystrophic Royal College of Surgeons (RCS) rats. In this study, we attempted to reveal the safety and influence of exogenous ChR2 gene expression. Adeno-associated virus (AAV) type 2 encoding ChR2 fused to Venus (rAAV-ChR2V) was administered by intra-vitreous injection to dystrophic RCS rats. However, rAAV-ChR2 gene expression was detected in non-target organs (intestine, lung and heart) in some cases. ChR2 function, monitored by recording visually evoked potentials, was stable across the observation period (64 weeks). No change in retinal histology and no inflammatory marker of leucocyte adhesion in the retinal vasculature were observed. Although antibodies to rAAV (0.01-12.21 mg ml À1 ) and ChR2 (0-4.77 mg ml À1 ) were detected, their levels were too low for rejection. T-lymphocyte analysis revealed recognition by T cells and a transient inflammation-like immune reaction only until 1 month after the rAAV-ChR2V injection. In conclusion, ChR2, which originates from Chlamydomonas reinhardtii, can be expressed without immunologically harmful reactions in vivo. These findings will help studies of ChR2 gene transfer to restore vision in progressed retinitis pigmentosa.
INTRODUCTION
Retinitis pigmentosa (RP) is a group of diseases in which a gene mutation results in the death of photoreceptor cells. At present, approximately 40 genes have been identified as the causative agents (http://www.sph.uth.tmc.edu/retnet/; provided in the public domain by the University of Texas Houston Health Science Center, Houston, TX, USA). The initial visual impairment in patients with RP is night blindness, and patients lose their vision in the final stage of this disease following visual field loss. 1 Many trials have been conducted to identify agents that can protect photoreceptors and delay vision loss, but effective treatments have not been developed against progressed RP.
Although photoreceptor cells are often degenerated in the case of progressed RP, other inner neurons, including retinal ganglion cells (RGCs) are preserved. 2 It would be ideal to utilise the remaining retinal neurons to restore vision. We have been studying light-gated cation-selective membrane channel protein channelrhodopsin-2 (ChR2) 3 to induce photoreceptor function in retinal neurons such as RGCs 4, 5 and ON bipolar cells. 6 We have already demonstrated that the responses induced by various stimulus frequencies (Hz) in ChR2-transduced rats are in no way inferior to those in normal rats, 7 as supported by the finding that ChR2-induced photocurrents are extremely fast. 8, 9 Visual function was also well analysed by using transgenic rats with ChR2 transduction into RGCs: the spatial frequencies based on behavioural responses of photoreceptordegenerated ChR2 transgenic rats were the same as those of normal rats. 10 These studies indicate that transfer of the ChR2 gene into the remaining retinal neurons is a useful method for restoring vision in progressed RP.
However, for clinical application of ChR2 therapy, some problems must be considered. First, this approach is a gene therapy. An immune response (mostly a problem with adenovirus-and herpes simplex virus-derived vectors) 11 may be caused by adeno-associated virus (AAV) and its incorporation into the host genome may lead to de-repression of tumour suppression genes. [12] [13] [14] Second, ChR2 is a protein originating from Chlamydomonas reinhardtii. It is important to study the systemic responses on virus vector application and longterm expression of the transgene product in humans. In this study, to reveal the safety and influence of exogenous ChR2 gene expression, we investigated the functional stability of the ChR2 gene and the possibility of harmful immune reactions caused by this gene therapy in a Royal College of Surgeons (RCS) rat model of RP.
RESULTS

Recording of visually evoked potentials (VEPs) in RCS rats
Although RGCs are maintained in aged RCS (rdy/rdy) rats, VEPs would be abolished because of the loss of light-evoked synchronous activities by photoreceptor cells. Indeed, VEPs were not evoked even by the maximum flash of the light-emitting diode in any of the 6-month-old RCS (ryd/rdy) rats. After confirmation of the loss of photoreceptor-derived function, AAV encoding ChR2 fused to Venus (rAAV-ChR2V) was administered by intra-vitreous injection into the left eye. The right eye was not treated and served as the control. At 2 weeks after the injection, VEPs were recorded in the right visual cortex. The amplitude peaked at 8 weeks but remained stable until 64 weeks after the injection (Figure 1 ). There was no recording from the left side of the visual cortex (data not shown). We could not record for longer periods than 64 weeks because the lifespan of RCS rats is about 2 years.
Viral dissemination to the organs
To determine systemic dissemination of rAAV after the injection, total ribonucleic acids were isolated from each organ after 6 months of rAAV-ChR2V administration. No rAAV-derived Venus expression was detected by reverse transcription-polymerase chain reaction (RT-PCR) analysis from the brain, liver, spleen and kidney ( Figure 2 ). As expected, we detected the appropriate Venus protein expression from the rAAV-transduced retinas. Venus expression was unexpectedly detected in other organs (heart, lung and intestine) in some cases.
Histological examination of rAAV-ChR2V-treated retina The rAAV-derived gene expression was investigated by observing whole-mounted retina. At 6 months after rAAV administration, the expression of ChR2V or Venus was observed by fluorescence microscopy (Figure 3 ). ChR2V was expressed in the plasma membrane of the retinal cells; on the other hand, Venus expression was observed in the cytoplasm of the rAAV-Venus-injected retina. Both of the rAAVderived proteins were expressed all over the retina, and there was some deflection of the retinal expression.
To assess the side effects of ChR2 gene transfer by using rAAV, histological studies were performed on paraffin-embedded and frozen sections. There was no obvious difference in the retinal morphology between the ChR2-injected and the age-matched untreated RCS (rdy/rdy) rats (Figures 4a and b) . However, intra-vitreous injection of lipopolysaccharide, which resulted in endotoxin-induced uveitis (EIU), in the RCS (+/+) rats caused substantial migration of inflammatory cells, mainly polymorphonuclear leucocytes, in the neural retina and vitreous humour (Figure 4d ).
When the retinal activities were studied in frozen sections by immunohistochemistry ( Figure 5 ), glial fibrillary acidic protein (GFAP) expression was restricted to the ganglion cell layers in the rAAV-ChR2V-treated retina ( Figure 5c ); however, GFAP expression was observed throughout the inner half of the retina in the untreated RCS ( Figure 5b ) and rAAV-Venus-injected RCS (Figure 5d ) rats. Nuclear factor-kB (NF-kB) expression was restricted to the ganglion cell layers in all the tested RCS rats, but it was markedly high in the rAAV-ChR2V-treated retinas (Figure 5h ). 
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Figure 2 Virus dissemination to the organs. At 6 months after the administration of rAAV-ChR2V, total ribonucleic acid was extracted from the retina, brain, testis, liver, kidney, intestine, lung and heart. The rAAV-derived gene was investigated by using RT-PCR analysis. As expected, a high copy number of the rAAV-derived gene expression was detected in the retina. The gene expression was also detected in the heart, lung and intestine in some cases.
Side effect of channelrhodopsin-2 gene transfer E Sugano et al after the development of EIU. Our study demonstrated that EIU caused leucocyte adhesion in the retinal venules (Figures 6c and d) . However, there was no difference in leucocyte adhesion between the untreated (Figure 6a ) and the rAAV-ChR2V-injected (Figure 6b ) RCS rats, which had received the rAAV injection 1 year previously.
Humoral immune responses to the viral vector and transgene
To assess the possibility of a systemic humoral immune response to the viral vector or transgene, we determined the antibody levels against the rAAV2 capsid and ChR2 in serum by enzyme-linked immunosorbent assay. In the rAAV-ChR2V-injected rats, rAAV2 capsid-specific antibodies were detected and showed the maximum production at 2 months after injection (0.01-12.21 mg ml À1 ; Figure 7a ). However, the titre was extremely low in this study compared with that in a previous report of intramuscular injection of AAV2 (200-400 mg ml À1 ). 16 The titre against the ChR2 protein was the maximum at 6 months post-injection. However, this level was also low (0-4.77 ± 2.55 mg ml À1 ) compared with the antibody level in serum of the immunized rabbit (1442.34 mg ml À1 ), which received a peptide injection to produce antibody to ChR2 forcibly ( Figure 7b ).
Analysis of T-lymphocyte subsets
Total T lymphocytes were gated with positive staining of anti-CD3. Then, the population of lymphocytes was confirmed by forward scatter (cell size) versus side scatter (cell granularity). Analysis of T lymphocyte subsets, namely CD4 + (T helper cells), CD8 + (cytotoxic Figure 4 Histological examination of rAAV-ChR2V-treated retina. rAAV-ChR2V was administered by intra-vitreous injection into the left eye of RCS (rdy/rdy) rats. After 64 weeks, their right (control) (a) and left (b) eyeballs were enucleated and stained with hematoxylin and eosin. As a model of inflammation, agematched RCS (+/+) rats were administered lipopolysaccharide (LPS) by intra-vitreous injection and their eyeballs were enucleated after 48 h. Retinal sections of untreated RCS (+/+) (c) and the LPS-treated (d) rats were studied. Substantial infiltration of inflammatory cells, which were mainly PMNLs in the neural retina (arrow) and vitreous humour (arrowhead), was observed in the retina of the LPS-treated rats.
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Side effect of channelrhodopsin-2 gene transfer E Sugano et al cells) and CD4 + CD25 + (T regulatory cells), was performed. The CD4 + /CD8 + ratio is a known indicator of the immunoregulatory status. 17, 18 Our results demonstrated that the CD4 + /CD8 + ratio after 1 week of the rAAV injection was higher than the pre-injection ratio ( Figure 8a ). This increase occurred in the case of both the rAAV-Venus and rAAV-ChR2V injections. In addition, the CD4 + /CD8 + ratio only 1 Changes in the protein immunoreactivities in the retina. Untreated RCS (+/+) (a and f) and RCS (rdy/rdy) (b and g) rats were used as the controls. rAAV-Venus (d and i) or rAAV-ChR2V (c and h) was administered by intra-vitreous injection into the left eye of RCS (rdy/rdy) rats. After 64 weeks, their eyeballs were enucleated. All the RCS rats were of the same age at the time of enucleation (2.2 years). As the negative control for staining, the first antibodies were replaced with non-immune mouse immunoglobulin G (e and j). DNA was counterstained with 4', 6-diamidino-2-phenylindole. GFAP expression was restricted to the ganglion cell and nerve fibre layers of the ChR2V-treated retina (c); however, it was observed throughout the inner half of the retina in the untreated RCS (b) and rAAV-Venus-injected RCS (d) rats. Nuclear factor-kB expression was restricted to the ganglion cell layers in all the tested RCS rats, but it was markedly high in the ChR2V-treated retina (h). Figure 6 Adverse effect of rAAV-ChR2V treatment on retinal leucocyte adhesion. To study the adverse effect of ChR2 treatment in RCS rats, their retinas were examined after 1 year of rAAV-ChR2V injection. As a model of inflammation, RCS (+/+) rats received an intra-vitreous injection of lipopolysaccharide (LPS) and were examined 48 h after the injection. Flat-mounted retinas labelled with concanavalinA lectin showed increased number of adherent leucocytes in the retinal vessels of the LPS-injected rats (c) compared with the untreated (a) and rAAV-ChR2V-injected (b) rats. High-magnification photography of the LPS-treated retinal vessels showed leucocyte adhesion more clearly (d).
Side effect of channelrhodopsin-2 gene transfer E Sugano et al month after the rAAV-ChR2V injection was higher than that before the injection. These data suggested that a change in the inflammation status occurred from 1 week to 1 month after rAAV administration. After this period, the ratios decreased to the pre-injection value and were stable for 1 year. To assess the inflammation status, we studied T regulatory cells. As shown in Figure 8b , a significant increase in the number of CD4 + CD25 + cells was observed at 1 week after the rAAVVenus and rAAV-ChR2V injections compared with the numbers before the injections. There was no significant difference in the inflammation status between the rAAV injections. As a positive control of inflammation, EIU also increased the population of CD4 + CD25 + cells, which is consistent with a report by Toda et al. 19 
DISCUSSION
The results of this study demonstrate that the strategy of restoration of vision and light responses in photoreceptor-degenerated RCS (rdy/rdy) rats by rAAV-ChR2V administration was technically feasible and safe. Most importantly, ChR2 function, which was confirmed by measuring VEPs, was not reduced over the whole observation period after rAAV-ChR2V administration (Figure 1) . A single administration of rAAV-ChR2V restored the light sensitivity over the lifespan of the rat model. The eye is considered to be an immunologically protected space. 20 This immune privilege is the result of multiple layers and mechanisms, including the blood-retina barrier and other physical barriers, such as the immunosuppressive microenvironment against deviant systemic immunity, that limit the production of pro-inflammatory effector cells. We predicted that systemic dissemination of a virus would be limited by these immune systems after intra-vitreous injection. To investigate the systemic dissemination of rAAV, ribonucleic acids were isolated from each organ and the expressions of the Venus protein, which was fused to rAAV-ChR2, were studied (Figure 2) . Venus expression was notable in the retina. Contrary to our expectations, the expression was also detected in the intestine, lung and heart in some cases. The RCS (rdy/rdy) animal model, which genetically causes loss of photoreceptors, is reported to have some breakdown of the blood-retina barrier or other mechanisms. [21] [22] [23] [24] Therefore, the rAAV vector might have been disseminated to the other organs. Supporting this hypothesis, the efficiency of rAAVderived gene transfer was higher in RCS rats than in normal rats (data not shown). This result suggests that some breakdown of the retinal barriers increased the permeability to rAAV.
The genomes transferred by rAAV tend to persist in cells mainly in an episomal, non-integrated form. 25 The transferred genomes in episomal form are diluted by cell division. However, when rAAVcarried genomes are inserted into chromosomes of cells with high proliferation ability, the genomes are preserved. There were some differences in gene delivery by rAAV among the samples obtained from the intestine, lung and heart. These differences might be the result of differences in the insertion forms of the rAAV genomes.
In gene therapy, tumour formation caused by the insertion of a transgene into the genome has been reported. [12] [13] [14] We did not observe tumour formation in any of the rats that received the rAAV injections (data not shown). For more information regarding tumour formation, further studies are needed by using methods such as Northern blotting, integration site analysis 26 and oncogene analysis.
We also investigated the inflammatory responses caused by the gene transfer by using the EIU model as a positive control of inflammation. EIU caused ocular inflammation, including leucocyte infiltration into the vitreous humour (Figure 4d ) and leucocyte adhesion to the retinal vessels (Figures 6c and d) . These findings are consistent with those of previous reports. 15, 27 However, we did not observe such inflammatory cells in the retinas treated with rAAV-Venus or rAAV-ChR2V. Therefore, rAAV-ChR2V administration did not induce inflammation arising from bacterial infection.
GFAP is reportedly expressed because of gliosis and hypertrophy of macroglial cells. 28 Moreover, GFAP is expressed in astrocytes in the retina usually, but in Müller cells under pathological or stress conditions. 29 GFAP was also reported to be upregulated in the brain astrocytes during the inflammatory response. 30 Beurel and Jope 31 revealed that GFAP upregulation is caused by the production of the inflammatory cytokine interleukin-6. The absence of GFAP upregulation by viral injection (Figures 5b-d) demonstrates the lack of glial activation derived from inflammation. Our study showed that GFAP was expressed throughout the retina in the untreated RCS rats and that the expression was decreased and restricted by the rAAV-ChR2V injection (Figure 5c ). These results reveal that activation of RGCs by ChR2 may have a protective effect on the inner retina. 32, 33 NF-kB expression in the retina was restricted to the ganglion cell layers in all Production levels of the antibodies to the AAV2 vector (a) and the therapeutic gene, ChR2 (b), were studied in RCS rats following a single intra-vitreous injection of rAAV-ChR2V. The time after injection is indicated. The antibody levels against both AAV2 and ChR2 were quite low compared with the antibody levels in serum of an immunized rabbit, which were considered as the effective dose to react with antigens.
Side effect of channelrhodopsin-2 gene transfer E Sugano et al the experiments and there was no staining of the other inner retinal cells, which was caused by stress. 34 We also demonstrated the potent expression of NF-kB p65 in the rAAV-ChR2V-injected retinas. These results are consistent with reports that constitutive NF-kB activity is the result of ongoing synaptic activity. 35, 36 The T-lymphocyte analysis demonstrated that the CD4 + /CD8 + ratio was higher in all the rAAV-treated rats at 1 week after the injection than before the injection, and in the rAAV-ChR2V-treated rats, the ratio was high at 1 month after injection (Figure 8a ). However, these increases were transient and returned to the pre-injection level. This expansion allows cross-talk between different types of cells in the ongoing immune response. 17 Kim and Lim 18 reported that CD4 + /CD8 + expansion is caused by bacterial infection. After 1 week, the ratio increased in all the rAAV-injected rats. Thus, there might have been some immune reactions such as antigen presentation to rAAV. At 1 month after the rAAV-ChR2V injection, the ratio increased again. As shown in Figure 1 , the maximum ChR2 function was recorded at 1 month in the visual cortex first. Thus, some immune reactions might have been induced by increased ChR2 expression but were well tolerated at 2 months after the injection.
Currently, the best characterized regulatory cells are CD4 + CD25 + T cells. 37 These cells can suppress host immune responses and modulate the immune responses in autoimmune diseases, allergy, transplantation and infectious diseases. 38, 39 CD25, an interleukin-2 receptor, is reported to be an inflammation marker on CD4 + lymphocytes. 18 In the EIU experiment, we observed expansion of CD4 + CD25 + cells, which is consistent with the report by Toda et al. 19 A significant increase in the number of CD4 + CD25 + cells was observed in both the rAAV-Venus and the rAAV-ChR2V rats at 1 week after the injections compared with the pre-injection values (Figure 8b ), although there was no significant difference in the results between the rAAV-Venus and the rAAV-ChR2V injections. 
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These results demonstrate that the inflammation-like immunological reaction was caused by AAV and not by ChR2.
To assess the possibility of a systemic humoral immune response to the viral vector or transgene product, we measured the antibody levels of the rAAV2 capsid and ChR2 in serum by enzyme-linked immunosorbent assay. Intra-vitreous injection caused relatively little antibody production ( Figure 7a ) compared with the different route of AAV injection used by Zhang et al. 16 Li et al. 40 demonstrated that a single intra-vitreous injection of AAV2 causes increased AAV antibody production at 2 months after injection. Our data are consistent with their report in terms of the timing of increase and the amount of antibody production (Figure 7a) . We anticipated that ChR2 expression would cause antibody production because ChR2 is not inherent to humans. However, the production levels were relatively low (Figure 7b ) and were insufficient to induce a humoral immune response.
In conclusion, an immune reaction can be caused by AAV administration and ChR2 protein expression, but will be well tolerated. It should be noted that the experiments were performed in rats and cannot be directly extrapolated to humans, who constitute a far more immunologically heterogeneous population. However, these findings will help studies of ChR2 gene transfer to restore vision in progressed RP.
MATERIALS AND METHODS Animals
In total, 59 (6-month-old male) RCS rats (43 dystrophic (rdy/rdy)); 16 nondystrophic (+/+) were used in this study (Table 1 ). The animals were maintained and used in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and the Guidelines for Animal Experiments of Tohoku University. All the animal experiments were conducted with the approval of the Animal Research Committee, School of Medicine, Tohoku University. To compare the functions, the control and treated rats were age-matched in each experiment.
Induction of EIU
As a model of ocular inflammation, 41 RCS (+/+) rats received a single intravitreous injection of 5 mg lipopolysaccharide from Escherichia coli (055:B5; Sigma, St Louis, MO, USA) in 5 ml phosphate-buffered saline (PBS) to cause EIU. After 48 h of lipopolysaccharide administration, the inflammation status was studied.
Preparation of AAV vector carrying the ChR2 gene construct
The N-terminal fragment (residues 1-315) of ChR2 (GenBank accession no. AF461397) was fused to a fluorescent protein, Venus, in frame at the end of the ChR2-coding fragment described previously. 5 The ChR2V or Venus gene was introduced into the EcoRI and HindIII sites of the 6P1 plasmid. 42 The synapsin promoter was exchanged for a hybrid cytomegalovirus enhancer/chicken b-actin promoter, 42 and AAV-ChR2V and AAV-Venus were constructed. The pAAV-RC and p-Helper plasmids were obtained from Stratagene (La Jolla, CA, USA). Semi-confluent 293T cells on 15-cm plates were co-transfected with split-packaging plasmids-AAV-ChR2V (or AAVVenus), pAAV-RC and p-Helper-by using a calcium phosphate-based protocol according to the manufacturer's instructions (Agilent Technologies, La Jolla, CA, USA). The rAAV vectors (rAAV-ChR2V, rAAV-Venus) were purified by using the method of Auricchio et al. [43] [44] [45] rAAV vector injection
The rAAV-ChR2V or rAAV-Venus vector was administered by intra-vitreous injection into the left eye of 6-month-old RCS (rdy/rdy) rats. In brief, the rats were anaesthetised by intramuscular injection of a mixture of ketamine (66 mg ml À1 ) and xylazine (33 mg kg À1 ). Under an operating microscope, the conjunctiva was incised to expose the sclera. A total volume of 5 ml of vector suspension at a concentration of 5Â10 12 genomic particles per ml was administered by intra-vitreous injection through the ora serrata with a 10-ml Hamilton syringe and a 32-gauge needle (Hamilton Company, Reno, NV, USA).
Recording of VEPs
VEPs were recorded by using Neuropack MEB-9102 (Nihon Kohden, Tokyo, Japan). The method of recording was derived from a combination of protocols used by Papathanasiou et al. 46 and Iwamura et al. 47 In brief, at least 7 days before the experiments, recording electrodes (silver-silver chloride) were placed epidurally on each side 7 mm behind the bregma and 3 mm lateral to the midline, and a reference electrode was placed epidurally on the midline 12 mm behind the bregma. Under ketamine-xylazine anaesthesia, the pupils were dilated with 1% atropine and 2.5% phenylephrine hydrochloride. The ground electrode clip was placed on the tail. Photic stimuli of 20-ms duration were applied at a frequency of 0.5 Hz and generated by pulse activation of a blue light-emitting diode with light-emitting wavelengths in the range 435-500 nm (peak, 470 nm). A total of 100 consecutive response waveforms were averaged for the VEP measurements.
Ribonucleic acid isolation and rAAV-derived protein detection by RT-PCR analysis
Total ribonucleic acids were extracted (TRIreagent; Sigma) from the retina, brain, lung, testis, liver, kidney, intestine, lung and heart. cDNA was synthesised (First-Strand cDNA synthesis kit; GE Healthcare, Piscataway, NJ, USA) and the tracer fusion protein, Venus, expression was investigated by using a semiquantitative RT-PCR method. As the individual internal control, we performed PCR with b-actin. The primer sequences were as follows: 5¢-TCATGAAGTGT GACGTTGACATCCGT-3¢ (sense) and 5¢-CCTAGAAGCATTTGCGGTGCAC GATG-3¢ (antisense) for b-actin; 5¢-GACGTAAACGGCCACAAGTT-3¢ (sense) and 5¢-GAACTCCAGCAGGACCATGT-3¢ (antisense) for Venus. Following electrophoresis on 1.0% agarose gel, DNA was detected by staining with GelRed (Biotium, Inc., Hayward, CA, USA).
Histology
After death, the eyeballs were enucleated, immersed in 4% paraformaldehyde in PBS overnight at 4 1C and embedded in paraffin. Serial sections (4 mm) of whole eyes were cut sagittally, through the cornea and parallel to the optic nerve, and stained with haematoxylin and eosin. Microscopic examination of the sections was then performed (AxioImager A1; Carl Zeiss, Tokyo, Japan).
The ChR2V expression profile in the retina was studied according to the method we previously described. 5 In brief, the eyes were fixed and the retinas were flat-mounted on slides. Venus fluorescence was visualised under a fluorescence microscope (BZ-9000; Keyence Corp., Osaka, Japan).
Immunohistochemistry
Rat eyes were fixed overnight at 4 1C in 4% paraformaldehyde in PBS (pH 7.4). The retinas were rinsed with PBS and immersed in 10, 20 and 30% sucrose in PBS at 4 1C. Samples were embedded in optimal cutting temperature compound (Sakura, Tokyo, Japan) under liquid nitrogen and stored at À80 1C. Cryosections (10 mm) of tissue were mounted on slides and air dried. Then, retinal sections were washed with PBS and treated for 15 min with 0.3% H 2 O 2 in methanol. After washing with PBS, the sections were incubated with mouse anti-rat NF-kB p65 (C-20) antibody (1:200; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and mouse anti-rat GFAP antibody (1:250; Nihon Millipore, Tokyo, Japan) in antibody diluent buffer (0.05% Tween-20, 3% bovine serum albumin and 3% goat serum in PBS) overnight at 4 1C. After washing with 0.05% Tween-20 in PBS, the sections were incubated with horseradish peroxidase-conjugated goat anti-mus immunoglobulin G as the secondary antibody for 1 h at room temperature. After washing with TBST (150 mM NaCl, 0.1% Tween-20 in 20 mM Tris-HCl), the immunohistochemical reactions were visualised by using an Envision DAB kit (Dako, Tokyo, Japan). The sections were counterstained with haematoxylin. As a negative control for staining, the first antibodies were replaced with non-immune mouse immunoglobulin G (Dako). The sections were observed under a microscope (AxioImager A1; Carl Zeiss).
Lectin labelling of the retinal vasculature and adherent leucocytes
Leucocytes adhering to the retinal vasculature were imaged by perfusion labelling with fluorescein isothiocyanate-coupled concanavalin A lectin (Vector Laboratories, Burlingame, CA, USA). 27 After deep anaesthesia, the chest cavity was opened, a 20-gauge perfusion cannula was introduced into the aorta and a part of the liver was excised. After injection of 20 ml PBS to remove erythrocytes and non-adherent leucocytes, 20 ml of fluorescein isothiocyanate-conjugated concanavalin A lectin (40 mg ml À1 ) was injected. Residual unbound concanavalin A was removed with PBS perfusion. After the eyeballs were enucleated, the retina was flat-mounted and imaged under a fluorescence microscope (Axiovert 40; Carl Zeiss).
Enzyme-linked immunosorbent assay
To detect serum antibodies to the rAAV2 capsid and the transgenic protein, ChR2, we coated enhanced protein-binding enzyme-linked immunosorbent assay plates with 10 9 viral particles per well of rAAV2 in 100 ml of 0.1 M sodium carbonate buffer (pH 9.6) and with 0.2 mg per well peptide coding for ChR2 by using a peptide coating kit (TaKaRa, Shiga, Japan) at 4 1C overnight. The wells were blocked with 10% fetal bovine serum-0.1% Tween in PBS for 30 min at 37 1C. Then, serum dilutions were added and incubated for 4 1C overnight. Dilutions of a rabbit anti-AAV2 capsid protein (American Research Product, Belmont, MA, USA) and a rabbit anti-ChR2 protein (TaKaRa) served as positive controls. The plates were incubated with horseradish peroxidaseconjugated anti-rabbit immunoglobulin G or anti-rat immunoglobulin G at 37 1C for 1 h in the presence of 3% goat serum. The reactions were visualised by adding one-step tetramethylbenzidine substrate (Promega, Tokyo, Japan). The reactions were stopped by adding 1 N HCl and read at 450 nm with a VERS Amax plate reader (Molecular Devices, Osaka, Japan). Each value was determined in triplicate.
Analysis of T lymphocytes
Peripheral blood CD4 + cells have a central role in regulating the cell-mediated immune response to infection. Often known as helper T cells, they act on other cells of the immune system to promote various aspects of the immune response, including immunoglobulin isotype switching and affinity maturation and enhanced activity of natural killer cells and cytotoxic T cells. CD4 + cells also act by releasing cytokines in response to antigenic stimulation. One of the major roles of CD4 + cells is the activation of macrophages. During the course of hepatitis C virus infection, two different immunological statuses can be observed. In the acute phase of infection, CD4 + helper T cells contribute to the induction and maintenance of a functional CD8 + cell response. In the chronic phase, T regulatory (CD4 + CD25 + ) cells suppress CD8 + cell responses, and thereby help the virus to persist. 48 It is important to calculate these ratios to observe the immunological status.
Before and after the rAAV injection, peripheral blood was collected from the tail vein. Lymphocytes were isolated with PharmLyse (BD Bioscience, San Jose, CA, USA). After isolation, a mixture of monoclonal antibodies (mAbs) specific for CD3 (conjugated with Alexa Fluor 647; AbD Serotec, Oxford, UK), CD4 (conjugated with PE-Cy5; BD Bioscience), CD8a (conjugated with R-PE; BD Bioscience) and CD25 (conjugated with fluorescein isothiocyanate; BD Bioscience) was added to the cells, which were then incubated at 4 1C overnight. Flow-cytometric analysis was performed by using FACS Calibur (BD Bioscience) after washing the cells with PBS. For gating and calculation, CellQuest software (BD Bioscience) was used. In the FACS analysis, 10 000 cells were examined for each sample.
Statistical analysis
Statistical analysis was performed by using GraphPad Prism (GraphPad Software, San Diego, CA, USA). The criterion for statistical significance was Po0.05 by Dunnett multiple comparison test.
